35 Matching Annotations
  1. Last 7 days
    1. Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

    1. Carlos del Rio. (2021, April 7). U.K. variant now dominant form of COVID in US ⁦@CDCDirector⁩ As predicted B.1.1.7 is now the predominant SARS-CoV-2 strain in the US. Let’s remember it is much more transmissible and likely also more severe. Vaccines do cover it. ⁦@ajc⁩ https://t.co/Wc4oaYkxqR [Tweet]. @CarlosdelRio7. https://twitter.com/CarlosdelRio7/status/1379816377356333057

  2. Apr 2021
    1. Trevor Bedford. (2021, January 14). After ~10 months of relative quiescence we’ve started to see some striking evolution of SARS-CoV-2 with a repeated evolutionary pattern in the SARS-CoV-2 variants of concern emerging from the UK, South Africa and Brazil. 1/19 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1349774271095062528

    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

    1. Lee, L. Y., Rozmanowski, S., Pang, M., Charlett, A., Anderson, C., Hughes, G. J., Barnard, M., Peto, L., Vipond, R., Sienkiewicz, A., Hopkins, S., Bell, J., Crook, D. W., Gent, N., Walker, A. S., Peto, T. E., & Eyre, D. W. (2021). SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. MedRxiv, 2021.03.31.21254687. https://doi.org/10.1101/2021.03.31.21254687

  3. Mar 2021
    1. Grint, D. J., Wing, K., Williamson, E., McDonald, H. I., Bhaskaran, K., Evans, D., Evans, S. J., Walker, A. J., Hickman, G., Nightingale, E., Schultze, A., Rentsch, C. T., Bates, C., Cockburn, J., Curtis, H. J., Morton, C. E., Bacon, S., Davy, S., Wong, A. Y., … Eggo, R. M. (2021). Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England. MedRxiv, 2021.03.04.21252528. https://doi.org/10.1101/2021.03.04.21252528

  4. Feb 2021
    1. Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W. M., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Saunders, K. O., Gnanakaran, S., Hengartner, N. W., Pajon, R., Smith, G., Dubovsky, F., Glenn, G. M., Korber, B. T., & Montefiori, D. C. (2021). SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines (SSRN Scholarly Paper ID 3777473). Social Science Research Network. https://papers.ssrn.com/abstract=3777473